The solute carrier family 18 member A1 (vesicular monoamine transporter) gene SLC18A1 is of particular interest because of its association with schizophrenia (6-10), autism (11) and bipolar illness (9) as well as with cancer (12, 13) . In the current study, the relationship of SLC18A1 expression with smoking and lung cancer was analyzed.
Materials and Methods
The association between smoking, SLC18A1 expression and overall survival in the lung cancer dataset in The Cancer Genome Atlas (TCGA) was evaluated. To access and analyze the data the following were used: Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov); University California Santa Cruz Xena browser (https://xenabrowser.net); and CbioPortal for Cancer Genomics (http://www.cbioportal.org/) SLC18A1 expression is quantified as RNAseq count. The normalized unit for count is log2(norm_count+1). The normalization calculation is described elsewhere (14) .
Data selection. The entire TCGA lung cancer data set was analyzed (1,299 cases).
The following features were assessed: Effect of SLC18A1 on survival; expression of SLC18A1 by smoking status; frequency of genetic alteration of SLC18A1 in lung cancer according to histology; SLC18A1 expression in the TCGA PanCan Atlas. Endpoints were death or last time-point the patient was known to be alive. Survival analyses were carried out by the method of Kaplan and Meier (15) .
Results
A total of 1,299 patients were included in the sample; 43.5% were women, 56.5% were men. Their mean age was 66±9 years. Table I lists the pathological stages of the tumors included.
The effect of SLC18A1 on survival is shown in Figure 1 . Note that higher expression of SLC18A1 was found to be associated with significantly increased survival of patients with adenocarcinoma (p=0.0058) but not of those with squamous carcinoma (p=0.96). Number of patients in each group is shown above corresponding error bar. The high/low survival cutoff was identified by methods described in the R2 web-based application (http://r2.amc.nl); the method divides the sample, in ascending order of gene expression, into two equal-sized groups.
In those with adenocarcinoma, increased SLC18A1 expression and increased survival (284 patients out of 564 total) were probably due to the fact that never-smokers reportedly have better survival than smokers (16) , as well as higher SLC18A1 expression (Figure 2) . In a separate analysis, SLC18A1 was more highly expressed in 527 squamous cell carcinomas compared to 364 adenocarcinomas (mean±SEM=4.5±0.08 versus 3.5±0.14, respectively).
Expression of SLC18A1 according to smoking status is shown in Figure 2 (p=0.035 one-way ANOVA). Lifelong never-smokers had the highest expression.
Frequency of alteration of SLC18A1 in 1,299 lung cancers according to histology is shown in Figure 3 . PDCD1 (the PD1 gene) and SLC18A1 have four significantly co-occurent alterations (p=0.011) in lung adenocarcinoma, suggesting that these two genes might play a similar role or need to interact (17) . PDCD1 alterations are shown in Table II. SLC18A1 expression in the TCGA PanCan Atlas was examined. The Pan Cancer Atlas includes the analyses of over 11,000 tumors from 33 of the most prevalent forms of cancer. Expression of SLC18A1 places it in group C5, immunologically quiet tumors ( Figure 4 ). This group consists mostly of lower grade brain gliomas, exhibiting the lowest lymphocyte and highest macrophage responses, dominated by M2 macrophages (18) . SLC18A1 is most highly expressed in pheochromocytoma and paraganglioma ( Figure 5 ). SLC18A1 expression in 7,903 PanCan Atlas samples is shown in Figure  6 . This gene is not highly expressed in most tumors but might represent a biomarker and a therapeutic target. Information on gene program score is included in the figure (19) .
Discussion
SLC18A1 acts to accumulate cytosolic monoamines into vesicles, using the proton gradient maintained across the vesicular membrane. The transporter is a site of action of drugs, including reserpine and tetrabenazine (20) . Its normal function is essential for the correct activity of the monoaminergic systems that have been implicated in neuropsychiatric disorders. SLC18A1 maps to chromosome 8p23.1, a region of genes associated with personality traits (21) . SLC18A1 rs1390938/Thr136Ile is associated with mood, depression, personality, and alcohol use in the general population (22, 23) . Individuals homozygous for the 'hyperfunction' allele (AA; Ile/Ile) appear to be more resilient to these disorders (24) . Many genes are related to personality, mental illness, and smoking (25, 26) . But of these genes, only SLC18A1 is known to be also involved in cancer (12, 13, 27) .
CANCER GENOMICS & PROTEOMICS
Immune checkpoint inhibitors (ICIs) have emerged as a new treatment option for patients with cancer, especially advanced NSCLC. ICIs can prolong survival, compared to chemotherapy alone, in ever-smokers. However, ICIs mostly fail to improve survival in never-smokers (28).
Rizvi et al. assessed the effects of smoking on mutations and pembrolizumab response in NSCLC (29) . According to the tumor molecular signature of smoking (frequency of C→A transversions in lung cancer exomes), Rizvi et al. defined tumor samples as transversion high (TH, eversmoking signature) or transversion low (TL, never-smoking signature). Patients with TH molecular signature had higher mutational burden and showed better clinical benefit from pembrolizumab. This suggests that smoking status might be a predictive marker for clinical benefit from ICIs. Indeed, the expression of PD1 and its ligands PD-L1 and PD-L2, which predict response to pembrolizumab and nivolumab, is heterogeneous within kirsten rat sarcoma virus (KRAS)-mutant NSCLC and suggests an inducible expression of PD-L1 by smoking (30) . Both Keytruda ® (pembrolizumab) and Opdivo ® (nivolumab) are monoclonal antibodies that bind to the PD1 receptor found on T-cells and block its interaction with PD-L1 and PD-L2 (31) . Two of the approved indications for Keytruda are based on a US Food and Drug Administration-approved test for tumor expression of PD-L1, namely NSCLC and gastric cancer. Opdivo is indicated for both these cancer types without this limitation. Interestingly, most types of cancer for which these drugs are indicated are associated with smoking (NSCLC, gastric cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, hepatocellular carcinoma, but not melanoma) (https://dailymed.nlm.nih.gov/dailymed/ index.cfm Search "Keytruda" and "Opdivo").
Figure 1. Survival analysis of patients with lung cancer. Note the significant effect of higher solute carrier family 18 member 1 (SLC18A1) expression [log2(norm_count+1)] on survival of those with adenocarcinoma (A), but the absence of such effect in those with squamous cell carcinoma (B).

Figure 2. Solute carrier family 18 member 1 (SLC18A1) expression (mean+SEM) stratified by smoking status in The Cancer Genome Atlas lung cancer data. The variation was significant (p=0.035 one-way ANOVA). Number of patients in each group is shown above corresponding error bar.
Smoking may be related to cancer in two distinct ways: i) Systemic suppression of the immune response producing cancer that is susceptible to Keytruda and Opdivo. ii) Direct irritation producing tumors not susceptible to these agents. Where both mechanisms are present, there might be intermediate susceptibility. For unknown reasons, a small proportion of TL neversmokers show clinical benefit from pembrolizumab. This small proportion may correspond with the frequency of alteration of SLC18A1 in lung cancer (Figure 3) . Because of the good response of this small group, it may be worthwhile assessing SLC18A1 expression prior to treatment and gene alteration as markers for potential clinical benefit from ICIs in never-smokers. If SLC18A1 expression is low or SLC18A1 is mutated, a never-smoker may respond well to ICIs, despite TL never-smoker mutation status. Higher SLC18A1 expression levels would cause the tumor to fall into the C5 immunologically-quiet group, as is the case with squamous cell carcinoma, and it would, therefore, be less likely to respond to ICIs (Figure 1) . SLC18A1 might complement other biomarkers currently under study in relation to PD1/PD-L1 inhibition (32) .
